JAGX Jaguar Health Inc.

1.37
-0.09  -6%
Previous Close 1.46
Open 1.51
Price To Book -34.25
Market Cap 8,358,836
Shares 6,101,340
Volume 371,871
Short Ratio
Av. Daily Volume 1,139,991

NewsSee all news

  1. Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York

    SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte, Jaguar's founder, president and CEO, will

  2. Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer

    Company's Legacy Animal Health Business Supports Focus on Human Health BenefitsSAN FRANCISCO, CA / ACCESSWIRE / September 18, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the

  3. Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico

    Puerto Rico Had the 7th Highest Cumulative Rate of HIV Infection in the Nation in 2016SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")

  4. Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel

    SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Jonathan Wolin, an accomplished healthcare and biotech

  5. Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs

    Company's Legacy Animal Health Business Supports Focus on Human Health BenefitsSAN FRANCISCO, CA / ACCESSWIRE / August 26, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 3Q 2019 with final data due 1Q 2020.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Protocol development for discussions with FDA.
Mytesi (crofelemer)
Inflammatory bowel disease (IBD)

Latest News

  1. Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York

    SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte, Jaguar's founder, president and CEO, will

  2. Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer

    Company's Legacy Animal Health Business Supports Focus on Human Health BenefitsSAN FRANCISCO, CA / ACCESSWIRE / September 18, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the

  3. Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico

    Puerto Rico Had the 7th Highest Cumulative Rate of HIV Infection in the Nation in 2016SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")

  4. Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel

    SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Jonathan Wolin, an accomplished healthcare and biotech

  5. Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs

    Company's Legacy Animal Health Business Supports Focus on Human Health BenefitsSAN FRANCISCO, CA / ACCESSWIRE / August 26, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the

  6. Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern

    SAN FRANCISCO, CA / ACCESSWIRE / August 22, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals,